Treatment of Lamivudine-Resistant Hepatitis B Infection in Post–Renal Transplant Patients With Adefovir Dipivoxil: Premiminary Results

• Published in: Transplantation proceedings Vol. 38; no. 9; pp. 3118 - 3120
• Main Authors: de Silva, H.J., Dassanayake, A.S., Manamperi, A., de Silva, A.P.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01-11-2006; Elsevier Science
• Subjects: Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Biological and medical sciences; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Medical sciences; Pharmacology. Drug treatments; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Tissue, organ and graft immunology; Antiretroviral agent; RNA-directed DNA polymerase; Hepatic disease; Transplantation; Homotransplantation; Kidney; Result; Viral hepatitis B; Surgery; Reverse transcriptase inhibitor; Nucleoside analog; Antiviral; Graft; Pyrimidine nucleoside; Human; Postoperative; Purine nucleotide; Acyclic nucleotide; Enzyme; Transferases; Enzyme inhibitor; Lamivudine; Patient; Organic phosphonate; Infection; Medicine; Resistance; Nucleotidyltransferases; Adefovir; Treatment; Urinary system; Dideoxynucleoside; Viral disease; Digestive diseases
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2006.08.186

We report the treatment outcome in six post–renal transplant patients with lamivudine-resistant hepatitis B virus (LR-HBV) infection using adefovir dipivoxil and followed for 6 to 18 months. Posttransplant immunosuppressive therapy was not altered. Adefovir dipivoxil effectively suppressed hepatitis B virus DNA and improved alanine transferase, although DNA suppression seemed dependent on continued therapy. Nephrotoxicity led to withdrawal of the drug in three patients. This may limit therapeutic usefulness in a significant proportion of post–renal transplant patients with LR-HBV infection.